Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Mepolizumab Injection
BIOLOGICAL
2 trials
Sponsors
Vibeke Backer
, Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions
Asthma
Chronic Rhinosinusitis with Nasal Polyps
Eosinophilic Granulomatosis With Polyangiitis
Phase 2
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
Recruiting
NCT05979051
Guangdong Hengrui Pharmaceutical Co., Ltd
Eosinophilic Granulomatosis With Polyangiitis
Start: 2023-11-16
End: 2028-12-31
Target: 166
Updated: 2025-12-04
Phase 4
Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks
Active, not recruiting
NCT05598814
Vibeke Backer
Asthma, Chronic Rhinosinusitis with Nasal Polyps
Start: 2023-04-01
End: 2025-08-31
Target: 58
Updated: 2025-03-30
Related Papers
Mepolizumab treatment is associated with physical activity and cardiorespiratory fitness irrespective of endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps: a randomised controlled trial.
2025-12-29